Forward-looking statements Integra LifeSciences J.P. Morgan Healthcare Conference January 2026 Slide 2 A global medtech leader dedicated to restoring lives Demonstrated leadership in $9B global market Extensive portfolio of best-in-class products Executing strategic transformation Strengthening operational foundation Enabling growth and innovation 19% LTM adjusted EBTIDA margin 62.8% LTM adjusted gross margin $1.6B LTM reported revenue $89M LTM operating cash flow Slide 3 Financial metrics shown for the tra ...

Financial Performance - Q3 2025 revenue grew organically by 5% compared to Q3 2024[8, 9] - Adjusted EPS for Q3 2025 was $054, a 317% increase compared to $041 in Q3 2024[7, 10] - Adjusted EBITDA margin for Q3 2025 was 195%, a 330 bps increase compared to 162% in Q3 2024[10] - Q3 2025 operating cash flow was $409 million with a free cash flow conversion of 619%[11] Segment Performance - Codman Specialty Surgical (CSS) Q3 2025 revenue was $2926 million, with organic growth of 71% compared to Q3 2024[13] - Tissue Technologies Q3 2025 revenue was $1095 million, a 03% organic decrease compared to Q3 2024[17] Guidance and Outlook - Q4 2025 reported revenue is projected to be between $420 million and $440 million, with organic growth ranging from -59% to -14%[26] - Full year 2025 reported revenue is projected to be between $162 billion and $164 billion, with organic growth ranging from -16% to -04%[27, 28] - Full year 2025 adjusted EPS is projected to be between $219 and $224[28]

Core Insights - Integra LifeSciences Holdings Corporation reported a total revenue of $402.1 million for Q3 2025, reflecting a 5.6% increase on a reported basis and a 5.0% increase on an organic basis compared to the previous year [4][8][29] - The company experienced a GAAP net loss of $(5.4) million, or $(0.07) per diluted share, an improvement from a net loss of $(10.7) million, or $(0.14) per diluted share, in Q3 2024 [5][28] - Adjusted net income for Q3 2025 was $41.6 million, or $0.54 per diluted share, compared to $31.7 million, or $0.41 per diluted share, in the prior year [5][39] Financial Performance - Total reported revenues of $402.1 million increased by 5.6% year-over-year, with a GAAP gross margin of 51.5%, down from 52.6% in Q3 2024 [4][28] - Adjusted EBITDA for Q3 2025 was $78.5 million, representing 19.5% of revenue, compared to $61.8 million, or 16.2% of revenue, in the prior year [4][36] - The company generated cash flow from operations of $40.9 million in the quarter, with total balance sheet debt at $1.8 billion and net debt at $1.6 billion [10][11] Segment Performance - Codman Specialty Surgical, which accounts for approximately 70% of revenues, reported total revenues of $292.6 million, showing reported growth of 8.1% and organic growth of 7.1% compared to Q3 2024 [6][29] - Tissue Technologies, representing about 30% of revenues, saw total revenues of $109.5 million, reflecting a reported decline of 0.5% and an organic decline of 0.3% compared to the previous year [10][29] 2025 Outlook - For Q4 2025, the company expects reported revenues in the range of $420 million to $440 million, indicating a reported growth of (5.1%) to (0.6%) and organic growth of (5.9%) to (1.4%) [12][13] - The full-year 2025 revenue guidance has been updated to a range of $1.620 billion to $1.640 billion, representing reported growth of 0.6% to 1.8% and organic growth of (1.6%) to (0.4%) [13] Strategic Initiatives - The company is implementing a comprehensive plan to strengthen its supply chain and quality management system, aiming to improve overall performance and drive transformation [3][15] - The relaunch of PriMatrix® and Durepair® was completed ahead of schedule through a dual sourcing supply strategy [8][15]